Around the world, laws regarding cannabis are rapidly changing. There are countries where cannabis is freely available for both medical and recreational use, and there are countries where cannabis remains illegal. The popularity and accessibility of cannabis and cannabinoids has fostered a belief for many that cannabis products are largely benign. There is, however, a body of evidence that documents the risks of cannabis and cannabinoids, along with growing evidence supporting the use of these compounds for some medical conditions. With the increasing availability of cannabis and cannabinoids like cannabidiol (CBD) for medical and recreational use, healthcare professionals must be knowledgeable about the evidence related to cannabis and cannabinoids when counseling both patients and colleagues.
In this Research Topic, we aim to outline the evidence for the therapeutic use of cannabinoids for specific medical conditions and the potential side effects associated with acute and chronic cannabis use. The contributions will include evidence from randomized, double-blind placebo-controlled trials where possible. Our goal is to provide healthcare professionals with the best evidence to support them in their conversations with patients about the risks and benefits of cannabis and cannabinoids. In addition, this collection aims to provide practical guidance about how to determine if cannabinoid pharmacotherapy makes sense in a given clinical scenario and how to manage cannabinoids in clinical practice if warranted.
This Research Topic will include submissions related to the therapeutic use of cannabis and cannabinoids as well as other risks and benefits of these compounds. Additional related topics may include the epidemiology of the use of cannabis products, common adverse effects of chronic cannabinoid pharmacotherapy and the mitigation or treatment of these adverse effects, the relationship of cannabinoids to opioid use, the treatment of cannabis use disorder, and the direction of the development of novel cannabinoid therapeutics.
Around the world, laws regarding cannabis are rapidly changing. There are countries where cannabis is freely available for both medical and recreational use, and there are countries where cannabis remains illegal. The popularity and accessibility of cannabis and cannabinoids has fostered a belief for many that cannabis products are largely benign. There is, however, a body of evidence that documents the risks of cannabis and cannabinoids, along with growing evidence supporting the use of these compounds for some medical conditions. With the increasing availability of cannabis and cannabinoids like cannabidiol (CBD) for medical and recreational use, healthcare professionals must be knowledgeable about the evidence related to cannabis and cannabinoids when counseling both patients and colleagues.
In this Research Topic, we aim to outline the evidence for the therapeutic use of cannabinoids for specific medical conditions and the potential side effects associated with acute and chronic cannabis use. The contributions will include evidence from randomized, double-blind placebo-controlled trials where possible. Our goal is to provide healthcare professionals with the best evidence to support them in their conversations with patients about the risks and benefits of cannabis and cannabinoids. In addition, this collection aims to provide practical guidance about how to determine if cannabinoid pharmacotherapy makes sense in a given clinical scenario and how to manage cannabinoids in clinical practice if warranted.
This Research Topic will include submissions related to the therapeutic use of cannabis and cannabinoids as well as other risks and benefits of these compounds. Additional related topics may include the epidemiology of the use of cannabis products, common adverse effects of chronic cannabinoid pharmacotherapy and the mitigation or treatment of these adverse effects, the relationship of cannabinoids to opioid use, the treatment of cannabis use disorder, and the direction of the development of novel cannabinoid therapeutics.